OPTIMA is an Innovative Medicines Initiative (IMI)-funded EU project aiming to ensure that every patient with lung, prostate and breast cancer has access to the most up-to-date individualized treatments and innovative therapies. It is doing this by strengthening shared decision-making using dynamic computer-interpretable guidelines, and using AI-driven technology and tools.

As part of Lungs Europe, ELF will form the OPTIMA Patient Advisory Group, which will comprise patients and patient representatives with lived experience of lung, breast or prostate cancer. ELF will work together with the European Cancer Patient Coalition (ECPC) to invite people with lived experience to join the group, and to manage the group over the lifetime of the project. The group will be made up of a maximum of 10 individuals.

OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.